The Relationship Between Brain Injury Biomarkers in Cerebrospinal Fluid and Blood of Patients After Cardiac Arrest and Prognosis

NCT06624488 · tracked via the Priya Life Science China tracker

Sponsor

Tang Ziren

Phase

Observational

Started

2023-01-01

Last updated

2025-02-21

Condition(s) studied

Cardiac Arrest (CA)Brain Injuries, Acute

Study summary

This study is a single-center, prospective, observational study. After successful cardiopulmonary resuscitation for patients with cardiac arrest, they will be transferred to the emergency intensive care unit for further standardized targeted temperature management. When evaluating that the patient meets the indications for lumbar puncture and there are no contraindications for lumbar puncture, lumbar puncture examinations will be completed immediately after return of spontaneous circulation (ROSC), at 24 hours of hypothermia, at 72 hours of hypothermia, and after rewarming. Routine cerebrospinal fluid examinations such as cerebrospinal fluid routine, cerebrospinal fluid biochemistry, and cerebrospinal fluid lactate will be sent for inspection. At the same time, 6 ml of cerebrospinal fluid will be retained and stored in a refrigerator at -80°C. After sample collection is completed, enzyme-linked immunosorbent assay (ELISA) will be used to detect markers such as NSE, HCH-L1, NFL, tau, MBP, GFAP, and S100β. While performing the lumbar puncture examination, peripheral blood will be collected. After centrifugation for 10 minutes (4000 revolutions), serum will be retained and stored in a refrigerator at -80°C to complete the examination of the above markers. After 3 months, the patient\'s neurological function prognosis will be followed up according to the Pittsburgh Cerebral Performance Category (CPC) scale.

Eligibility

Sex

ALL

Min age

18 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: * Age ≥ 18 years old. * Still lack of directive movements after restoration of spontaneous circulation through cardiopulmonary resuscitation. * Advanced life support and targeted temperature management are carried out within 6 hours after return of spontaneous circulation (ROSC). Exclusion Criteria: * Patients with contraindications for lumbar puncture (severe cerebral edema indicated by brain imaging, disappearance of basal cisterns or occult intracranial mass lesions, receiving antiplatelet and anticoagulant therapy, and those with coagulation disorders). * Pregnant patients. * Patients with concomitant traumatic brain injury, stroke, cerebral hemorrhage and other diseases. * Patients whose families do not agree to be enrolled.

Primary outcome measure(s)

Neurologic prognosis — 3 months
Patients will be followed up for neurologic prognosis according to the Pittsburgh Cerebral Performance Category (CPC) scale at 3 months after disease onset.The CPC score ranges from 1 to 5, with 1 indicating good performance, 2 indicating moderate disability, 3 indicating severe disability, 4 indicating vegetative state and 5 indicating brain death or death.

Trial sites (1)

Facility	City	Region	Status
Beijing chaoyang hospital	Beijing	China	Recruiting

More Tang Ziren trials in China

The Impact of Targeted Temperature Management Duration on Thrombin Function in Cardiac Arrest Patients Active, not recruiting

The Safety and Efficacy of Median Nerve Electrical Stimulation for Improving Neurological Function Prognosis in Patients With Cardiac Arrest Starting soon

Butylphthalide's Safety and Efficacy for Improving Neurological Function Prognosis in Patients With Cardiac Arrest (BNCA Trial) Recruiting

Neuroprotective Effect of Butylphthalide for Cardiac Arrest Patients Recruiting

Resting Energy Expenditure and Substrate Consumption in Cardiac Arrest Patients Under Target Temperature Management Recruiting

Other trials for the same condition

Effect of Target Temperature Management on Intestinal Flora and Its Metabolites in Patients With Cardiac Arrest Starting soon

TNF-α Antagonists Mitigate Systemic Inflammatory Response After Cardiac Arrest. Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06624488 on ClinicalTrials.gov ↗ ← All trials in China